Corcept医疗 CORT 深 沪
已收盘 05-15 16:00:00 美东时间
56.37
-1.930
-3.31%
华盛通- 最 高57.88
- 今 开57.44
- 成交量 87.47万股
- 最 低 56.09
- 昨 收 58.30
- 总市值 60.51亿
- 52周最高 91.00
- 市盈率 静 68.90
- 换手率 0.81%
- 52周最低 28.6601
- 委 比 -18.72%
- 总股本 1.07亿
- 历史最高 117.33
- 量 比 0.61
- 振 幅 3.07%
- 历史最低 1.27
- 每 手 1
- 风险率 17.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Corcept Therapeutics climbs on UBS upgrade
Corcept Therapeutics (CORT) jumped more than 7% on Wednesday after the stock was upgraded to Buy from Neutral by UBS Group. The brokerage firm also raised its price target to $72 from $44, implying ne...
05-13 23:37
UBS Upgrades Corcept Therapeutics to Buy, Raises Price Target to $72
UBS analyst Ashwani Verma upgrades Corcept Therapeutics (NASDAQ:CORT) from Neutral to Buy and raises the price target from $44 to $72.
05-13 20:43
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
Corcept Therapeutics Signals Big Growth After Key Wins
Corcept Therapeutics (($CORT)) has held its Q1 earnings call. Read on for the m...
05-05 08:20
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug
FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed technical indicators in focus.
05-04 23:22
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88
Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $73 to $88.
05-02 01:36
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortfall, and raised 2026 sales outlook.
05-01 22:52
U.S. RESEARCH ROUNDUP- Caterpillar, Textron, Wesco International
U.S. RESEARCH ROUNDUP- Caterpillar, Textron, Wesco International May 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Caterpillar, Textron and Wesco International, on Friday. HIGHLIGHTS * Arrowhead Pharmaceuticals ARWR.
05-01 15:29
